title: Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
authors.affiliation: Baylor University Medical Center, Dallas, Texas.
authors.forename: G B
authors.initials: GB
authors.lastname: Klintmalm
authors.forename: R
authors.initials: R
authors.lastname: Goldstein
authors.forename: T
authors.initials: T
authors.lastname: Gonwa
authors.forename: R H
authors.initials: RH
authors.lastname: Wiesner
authors.forename: R A
authors.initials: RA
authors.lastname: Krom
authors.forename: B W
authors.initials: BW
authors.lastname: Shaw
authors.forename: R
authors.initials: R
authors.lastname: Stratta
authors.forename: N L
authors.initials: NL
authors.lastname: Ascher
authors.forename: J W
authors.initials: JW
authors.lastname: Roberts
authors.forename: J
authors.initials: J
authors.lastname: Lake
mesh_terms: D000206:Actuarial Analysis; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D000305:Adrenal Cortex Hormones; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D016559:Tacrolimus